Utah Medical Products, Inc. develops, manufactures and distributes medical devices for the healthcare industry. The company is headquartered in Midvale, Utah.
| Revenue (TTM) | $34.92M |
| Gross Profit (TTM) | $20.14M |
| EBITDA | $13.39M |
| Operating Margin | 34.80% |
| Return on Equity | 8.81% |
| Return on Assets | 5.97% |
| Revenue/Share (TTM) | $10.96 |
| Book Value | $38.83 |
| Price-to-Book | 1.64 |
| Price-to-Sales (TTM) | 5.89 |
| EV/Revenue | 3.36 |
| EV/EBITDA | 11.23 |
| Quarterly Earnings Growth (YoY) | 6.80% |
| Quarterly Revenue Growth (YoY) | -12.10% |
| Shares Outstanding | $2.85M |
| Float | $2.77M |
| % Insiders | 7.20% |
| % Institutions | 77.54% |
Volatility is currently expanding
Utah Medical's Q3 earnings per share rise 7% year over year despite a 12.1% revenue decline, aided by lower operating expenses. Management expects a smaller revenue decline for full-year 2026.
SALT LAKE CITY, UT / ACCESS Newswire / October 22, 2026 / Utah Medical Products, Inc. (NASDAQ:UTMD) reports third quarter (3Q) and first nine months (9M) of calendar year 2026 financial results that include changes from the prior year's same period results. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros.
Utah Medical's Orion acquisition, strong cash reserves, improving margins and product expansion efforts support growth prospects and continued shareholder returns.
SALT LAKE CITY, UT / ACCESS Newswire / October 5, 2026 / Utah Medical Products, Inc. (Nasdaq:UTMD) is offering to purchase up to 650,000 shares of its common stock at $75.00 per share. The Offer was initially scheduled to expire at 5:00 p.m.
SALT LAKE CITY, UT / ACCESS Newswire / September 25, 2026 / Utah Medical Products, Inc. (Nasdaq:UTMD) is offering to purchase up to 650,000 shares of its common stock at $75.00 per share. The conditions of the Offer are explained in detail in the SEC Form TO Offer to Purchase and Letter of Transmittal filed with the SEC at https://www.sec.gov/Archives/edgar/data/706698/000109690626001428/0001096906-26-001428-index.html The Offer is scheduled to expire at 5:00 p.m.
SALT LAKE CITY, UT / ACCESS Newswire / September 24, 2026 / Utah Medical Products, Inc. (NASDAQ:UTMD) is offering to purchase up to 650,000 shares of its common stock at $75.00 per share. The $75.00 per share price represents a 17% premium over the average daily closing price of the stock during the last twelve months, and a 21% premium over the average daily closing price of the stock during the last twenty-four months.
SALT LAKE CITY, UT / ACCESS Newswire / September 15, 2026 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces today that it intends to repurchase at a price of $75.00 per share up to 650,000 of its shares, if tendered and not withdrawn by stockholders on or before October 7, representing approximately 20% of its currently outstanding shares. The offering price is 17% higher than the average daily closing price of UTMD shares trading in the open market during the last twelve months, and 21% higher than the average daily closing price of UTMD shares trading during the last two years.
SALT LAKE CITY, UT / ACCESS Newswire / August 31, 2026 / Femcare Ltd. ("Femcare"), a wholly-owned subsidiary of Utah Medical Products, Inc. (Nasdaq:UTMD), announces that it has purchased the entire ordinary share capital of Orion Medical Supplies Ltd ("ORION") of the United Kingdom.
SALT LAKE CITY, UT / ACCESS Newswire / August 4, 2026 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty-one cents ($.31) per share of common stock payable on October 5, 2026 to stockholders of record at the close of business on September 17, 2026. This is a 1.6% increase over the dividend declared in the same quarter of the prior year.
UTMD's Q2 earnings per share decline 10.1% year over year, while quarterly revenues face pressure from lost customers and slower new business growth.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on UTMD and any ticker you trade — then tracks every position and per-strategy win rate.
